liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry
Jagiellonian University.
Jagiellonian University.
Jagiellonian University.
Schwarzwald Baar Klinikum Villingen Schwenningen.
Show others and affiliations
2009 (English)In: AMERICAN HEART JOURNAL, ISSN 0002-8703, Vol. 158, no 4, 569-575 p.Article in journal (Refereed) Published
Abstract [en]

Background There are conflicting data on the clinical benefit from early administration of abciximab from a large randomized trial and a registry. However, both sources suggest that a benefit may depend on the baseline risk profile of the patients. We evaluated the role of early abciximab administration in patients with ST-segment-elevation myocardial infarction (STEMI) referred for primary percutaneous coronary intervention stratified by the STEMI Thrombolysis In Myocardial Infarction (TIMI) risk score. Methods A total of 1,650 patients were enrolled into the EUROTRANSFER Registry. One thousand eighty-six patients received abciximab (66%). Abciximab was administered early in 727 patients (EA) and late in 359 patients (LA). We used the TIMI risk score for risk stratification. Patients with scores 3 constituted the high-risk group of 616 patients (56.7%), whereas 470 patients formed the low-risk cohort. Factoring in the timing of the abciximab administration resulted in 4 groups of patients who were compared for mortality at 1 year: EA/high-risk (n = 413); LA/high-risk (n = 203); EA/low-risk (n = 3 14); LA/low-risk (n = 156). Baseline difference was accounted for by means of propensity score. Results In high-risk patients, 1-year mortality was significantly lower with early abcximab compared to late administration (8.7% vs 15.8%; odds ratio 0.51, CI 0.31-0.85, P = .01). In multivariable Cox regression analysis, both early abciximab administration and patients risk profile (TIMI score :3) were identified as independent predictors of 1-year mortality. Conclusions Early abciximab administration before transfer for percutaneous coronary intervention in STEMI shows lower mortality at 1-year follow-up. This effect is confined to patients with higher risk profile as defined by TIMI risk score andgt;= 3.

Place, publisher, year, edition, pages
2009. Vol. 158, no 4, 569-575 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-51402DOI: 10.1016/j.ahj.2009.08.008OAI: diva2:274611
Available from: 2009-10-30 Created: 2009-10-30 Last updated: 2013-09-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Janzon, Magnus
By organisation
Cardiology Faculty of Health SciencesDepartment of Cardiology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 45 hits
ReferencesLink to record
Permanent link

Direct link